1. Home
  2. ACHV vs MDXG Comparison

ACHV vs MDXG Comparison

Compare ACHV & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Achieve Life Sciences Inc.

ACHV

Achieve Life Sciences Inc.

N/A

Current Price

$7.59

Market Cap

618.0M

Sector

Health Care

ML Signal

N/A

Logo MiMedx Group Inc

MDXG

MiMedx Group Inc

N/A

Current Price

$4.27

Market Cap

625.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ACHV
MDXG
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
618.0M
625.6M
IPO Year
2018
2007

Fundamental Metrics

Financial Performance
Metric
ACHV
MDXG
Price
$7.59
$4.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$14.67
$9.00
AVG Volume (30 Days)
1.1M
1.5M
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.29
EPS
N/A
N/A
Revenue
N/A
$418,630,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$13.02
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.99
52 Week Low
$2.55
$3.03
52 Week High
$7.34
$7.97

Technical Indicators

Market Signals
Indicator
ACHV
MDXG
Relative Strength Index (RSI) 73.79 55.75
Support Level $4.04 $4.09
Resistance Level N/A $4.47
Average True Range (ATR) 0.33 0.21
MACD 0.08 -0.01
Stochastic Oscillator 98.71 75.17

Price Performance

Historical Comparison
ACHV
MDXG

About ACHV Achieve Life Sciences Inc.

Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

About MDXG MiMedx Group Inc

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Share on Social Networks: